Literature DB >> 3265417

Structure and expression of lck transcripts in human lymphoid cells.

R M Perlmutter1, J D Marth, D B Lewis, R Peet, S F Ziegler, C B Wilson.   

Abstract

The murine lck gene encodes a membrane-associated protein tyrosine kinase that has been implicated in lymphocyte oncogenesis. Here we report the structure of normal human lck transcripts and the pattern of expression of these transcripts in developing thymus and in peripheral T cell subsets. The human lck gene encodes a 509 amino acid polypeptide that is closely related to the murine lck-encoded protein throughout its length. Analysis of the deduced amino acid sequence of human p56lck demonstrates that an amino-terminal domain, widely divergent among the seven known src family members, has been conserved between murine and human p56lck, and thus probably includes sequences crucial to the lymphocyte-specific function of this molecule. Human lck transcripts were detected in CD4+ and CD8+ T cells, in partially purified B cells, and in Epstein-Barr virus-immortalized B cell lines, but not in monocytes, granulocytes, or in nonhematopoetic cell types. Human lck transcripts are readily detectable in fetal thymocytes at 70 days of gestation, but not at 57 days of gestation, indicating that lck expression appears coordinately with the appearance of lymphoid cells in the developing thymus. Thus lck gene expression is a marker for cells of the lymphocyte lineage in man. We conclude that the lck gene probably participates in a signal transduction pathway uniquely present in lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265417     DOI: 10.1002/jcb.240380206

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  26 in total

1.  Incomplete protein packing as a selectivity filter in drug design.

Authors:  Ariel Fernández
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

2.  Packing defects as selectivity switches for drug-based protein inhibitors.

Authors:  Ariel Fernández; Ridgway Scott; R Stephen Berry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

3.  Feature-similarity protein classifier as a ligand engineering tool.

Authors:  Sridhar Maddipati; Ariel Fernández
Journal:  Biomol Eng       Date:  2006-10-10

4.  A tyrosine kinase profile of prostate carcinoma.

Authors:  D Robinson; F He; T Pretlow; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Cell-type-specific tyrosine phosphorylation of the herpes simplex virus tegument protein VP11/12 encoded by gene UL46.

Authors:  George Zahariadis; Melany J Wagner; Rosalyn C Doepker; Jessica M Maciejko; Carly M Crider; Keith R Jerome; James R Smiley
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

6.  The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.

Authors:  L B Vogel; D J Fujita
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  Control of protein splicing by intein fragment reassembly.

Authors:  M W Southworth; E Adam; D Panne; R Byer; R Kautz; F B Perler
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

8.  tkl is the avian homolog of the mammalian lck tyrosine protein kinase gene.

Authors:  L M Chow; M J Ratcliffe; A Veillette
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.

Authors:  I Stefanová; M W Saville; C Peters; F R Cleghorn; D Schwartz; D J Venzon; K J Weinhold; N Jack; C Bartholomew; W A Blattner; R Yarchoan; J B Bolen; I D Horak
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Predominant expression and activation-induced tyrosine phosphorylation of phospholipase C-gamma 2 in B lymphocytes.

Authors:  K M Coggeshall; J C McHugh; A Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.